Breast cancer is the most common cancer among women in the United States with a lifetime risk of 1 in 8 (12%).1 Multiple risk factors for breast cancer have been identified and include gender, age, race, benign breast disease (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS]), age at menarche, parity, breast feeding, diethylstilbestrol (DES) exposure, early breast radiation, hormone replacement therapy, obesity, alcohol intake, family history, and genes. Based on all these factors, breast cancer risk assessment can be difficult, but is necessary to provide women with the most accurate estimate of their risk and the most appropriate risk management options. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Risk Reduction (in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org) provide recommendations for the management of breast cancer risk based on many of these risk factors, but one of the most important risk factors is family history and/or genetics.
The authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors.
American Cancer Society. Breast Cancer Overview. Available at: http://www.cancer.org/Cancer/BreastCancer/OverviewGuide/breast-cancer-overview-key-statistics. Accessed August 23 2010.
ArunBStrongL. Breast cancer genetic syndromes. In: SingletarySERobbGLHortobagyiGN eds. Advanced Therapy of Breast Disease 2nd edition. Hamilton, Ontario: B.C. Decker, Inc.; 2004:75–83.
SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:75–89.
KingMCWieandSHaleK. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001;286:2251–2256.
NarodSABrunetJSGhadirianP. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet2000;356:1876–1881.
HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:1633–1637.
RebbeckTRFriebelTLynchHT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2004;22:1055–1062.
KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:1609–1615.
WhittemoreASGongGItnyreJ. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet1997;60:496–504.
ActonRTBurstNMCasebeerL. Knowledge, attitudes, and behaviors of Alabama's primary care physicians regarding cancer genetics. Acad Med2000;75:850–852.
ReadyKJDanielsMSSunCC. Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome. J Cancer Educ2010;25:401–404.
BeversTBArmstrongDKArunB. NCCN clinical practice guidelines in oncology: breast cancer risk reduction. Version 12010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf. Accessed August 23 2010.
GailMHBrintonLAByarDP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989;81:1879–1886.
ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643–651.
TyrerJDuffySWCuzickJ. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med2004;23:1111–1130.
MurffHJSpigelDRSyngalS. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA2004;292:1480–1489.
DalyMBAxilbundJEBuysS. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Version 12010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed August 23 2010.
BeversTBAndersonBOBonaccioE. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Version 12010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf. Accessed August 23 2010.